Resources
Did you mean
Millennium Pharmaceuticals Inc. (154 results)
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Millennium Initiates Phase II Clinical Trial With VELCADE and Rituximab in Patients With Indolent Non-Hodgkin's Lymphoma
- In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a multicenter phase II clinical trial of VELCADE Bortezomib for injection in combination with rituximab in patients with relapsed or refractory indolent follicular and marginal zone non-Hodgkin's lymphoma. The randomized study will assess efficacy, overall safety and tolerability of the...
- White papers 2004-05-13
- Millennium Announces Assignment of Medicare Code for Velcade (Bortezomib) for Injection
- In this article Millennium Pharmaceuticals, Inc. informs that the Center for Medicare and Medicaid Services CMS has qualified VELCADE for pass-through status and assigned it to a Healthcare Common Procedure Coding System HCPCS whereby hospitals may obtain reimbursement for VELCADE under the hospital outpatient prospective payment system OPPS effective October...
- White papers 2003-09-26
- Millennium Announces Preliminary Phase I and Phase II Findings of VELCADE (Bortezomib) for Injection in Studies of Non-Hodgkin's Lymphoma and Solid Tumors
- In this article Millennium Pharmaceuticals, Inc. discusses the results of several clinical trials with its novel oncology product VELCADE, in which early signs of anti-tumor activity were observed with VELCADE as both a single agent and in combination with other therapies. VELCADE Studied as a Single Agent in Non-Hodgkin's Lymphoma...
- White papers 2003-06-02
- Millennium Seeks European Regulatory Approval for Bortezomib (VELCADE) 3.5MG Powder for Solution for Injection
- In this article Millennium Pharmaceuticals, Inc. informs that it has submitted a complete Marketing Authorization Application MAA to the European Agency for the Evaluation of Medicinal Products EMEA for the approval of bortezomib VELCADE as a treatment for relapsed and refractory multiple myeloma. This application was submitted approximately one week...
- White papers 2003-02-04
- Millennium Submits New Drug Application for VELCADE (Bortezomib) for Injection
- In this article Millennium Pharmaceuticals, Inc. informs that it has submitted a New Drug Application NDA with the U.S. Food and Drug Administration FDA for approval to market VELCADE as a treatment for relapsed and refractory multiple myeloma. In June 2002, VELCADE was granted fast-track status by the FDA as...
- White papers 2003-01-22
- Millennium Initiates Pivotal Phase III Clinical Trial Comparing VELCADE (Bortezomib) for Injection With High-Dose Dexamethasone in Patients With Multiple Myeloma
- In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a pivotal phase III clinical trial of VELCADE (formerly known as MLN341, LDP-341 and PS-341) in patients with multiple myeloma, the second most common hematologic cancer. The company also announced they have filed the trade name VELCADE, for trademark registration,...
- White papers 2002-06-11
- Millennium Announces VELCADE (Bortezomib) for Injection has Significantly Extended Survival in Phase III (APEX) Trial of Patients With Relapsed Multiple Myeloma
- In this article Millennium Pharmaceuticals, Inc. discuses their final survival endpoint analysis in the phase III confirmatory APEX study comparing patients receiving VELCADE to those receiving high-dose dexamethasone, VELCADE produced a statistically significant survival benefit. The study was designed to include survival as a secondary endpoint and allowed crossover for...
- White papers
- Millennium Initiates Phase II Clinical Trial With VELCADE (Bortezomib) for Injection in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a multicenter phase II clinical trial of VELCADE in patients with relapsed or refractory mantle cell lymphoma. The single-arm, open-label, three-stage study will assess time to progression, response rate, duration of response and overall survival in patients with relapsed or...
- White papers
- Millennium Announces Promising Early Study Results With VELCADE (Bortezomib) for Injection Combined With Doxil in Patients With Advanced Multiple Myeloma
- In this article Millennium Pharmaceuticals, Inc. discusses the preliminary phase I study results, examining the use of its novel oncology product, VELCADE, in combination with DOXILR doxorubicin liposome injection for the treatment of patients with advanced stage multiple myeloma that have failed multiple prior treatments. Also presented was a combination...
- White papers
- Millennium Initiates Phase II Clinical Trial With Velcade (Bortezomib) for Injection fn Patients With Advanced Non-Small Cell Lung Cancer
- In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase II clinical trial of VELCADE in patients with stage IIIb locally advanced or stage IV metastatic non-small cell lung cancer NSCLC. The randomized, open-label study will assess response rates of patients with previously treated NSCLC to treatment with...
- White papers
- Millennium Initiates Phase II Clinical Trial With VELCADE (Bortezomib) for Injection in Patients With Colorectal Cancer
- In this article Millennium Pharmaceuticals, Inc. discusses the recent initiation of a phase II clinical trial of VELCADE in patients with colorectal cancer. The randomized, open-label study assesses the response rates of patients with refractory metastatic colorectal cancer to treatment with VELCADE alone or VELCADE plus CamptosarR irinotecan hydrochloride injection....
- White papers
Additional Resources
- Takeda cancer drug
- Japanese drug maker Takeda Pharmaceutical Co.'s Velcade has been given FDA approval for use on patients with previously untreated multiple myeloma. Velcade, previously approved for multiple myeloma patients who had tried another treatment unsuccessfully, was developed by Millennium Pharma, a biotechnology company recently acquired by Takeda...
- Articles 2008-07-14
- The International Myeloma Foundation Says Previously Untreated Patients Could Benefit from FDA Approval of VELCADE® for 'Front-Line' Use
- New Indication Provides Treatment-Free Interval As an Option NORTH HOLLYWOOD, Calif. -- The International Myeloma Foundation IMF - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today applauded the decision by the US Food and Drug Administration...
- Articles 2008-06-23
- New Data Support High Complete Remission Rates With VELCADE® for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
- - Five Oral Presentations at ASCO Annual Meeting Will Further Demonstrate the Strength of VELCADE Combinations in Front-line Multiple Myeloma - CAMBRIDGE, Mass., May 16 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced that new data from VELCADE clinical studies are scheduled to be featured...
- Articles 2008-05-16
- Current and Emerging Drugs Have Not Yet Shown an Advantage in Survival Over Velcade in the Treatment of Relapsed Multiple Myeloma
- A Drug Used in Combination with Velcade That Could Improve Overall Survival Would Earn a 45 Percent Patient Share, According to a New Report from Decision Resources WALTHAM, Mass., May 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical...
- Articles 2008-05-08
- Acquisitive Takeda snaps up biotech Millennium
- TAKEDA Pharmaceutical of Japan announced plans to purchase US biotech firm Millennium Pharmaceutical in a deal valued at nearly $9 billion. The deal is the largest transaction involving a Japanese company so far this year and brings the Osaka-based Takeda a new therapeutic area-cancer treatments. Millennium Pharmaceutical's...
- Articles 2008-05-01
- Zacks Bull and Bear of the Day Highlights: Millennium Pharmaceuticals, Arkansas Best, Apple, Inc., Johnson Controls and Telefonica
- CHICAGO -- Zacks Equity Research highlights Millennium Pharmaceuticals (Nasdaq: MLNM) as the Bull of the Day and Arkansas Best Corporation (Nasdaq: ABFS) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Apple, Inc. (Nasdaq: AAPL), Johnson Controls (NYSE: JCI) and Telefonica (NYSE: TEF). Full analysis...
- Articles 2008-04-14
- Publication of Clinical Results Underscores VELCADE® For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
- -- Trial results of combination therapy VELCADE, melphalan and prednisone reported a 32 percent complete remission rate with 85 percent of patients alive at three years -- CAMBRIDGE, Mass., March 13 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced the publication of updated results of the Phase...
- Articles 2008-03-13
- Eleventh Annual Lehman Brothers Global Healthcare Conference to Webcast Millennium Presentation
- CAMBRIDGE, Mass., March 12 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that its presentation at the Eleventh Annual Lehman Brothers Global Healthcare Conference will be webcast live and may be accessed by visiting the Investors section of the Company's website, http://www.millennium.com/. (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ) ...
- Articles 2008-03-12
- Cowen & Company 28th Annual Healthcare Conference to Webcast Millennium Presentation
- CAMBRIDGE, Mass., March 10 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that its presentation at the Cowen & Company 28th Annual Healthcare Conference will be webcast live and may be accessed by visiting the Investors section of the Company's website, http://www.millennium.com/. (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ) ...
- Articles 2008-03-10
- << Previous
- page 1 of 1
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
- Hardware problem. Software problem. With AT&T Tech Support 360, at least it's not your problem.
-
With AT&T Tech Support 360, you'll have certified, U.S. based technicians on call 24/7 to help keep your computers, connections, software and peripherals up to speed for just 82¢ a day.
- Reduce computer downtime. Click to learn more.
